Safety and Efficacy of Rifampicin in treatment of Rhinoscleroma, Single Institutional Experience on patients over two years period
Bakhiet, A., Abd Hakeem, A., Saleh, E., Sherif, M., Mohammed, A. (2021). Safety and Efficacy of Rifampicin in treatment of Rhinoscleroma, Single Institutional Experience on patients over two years period. EKB Journal Management System, 7(2), 23-36. doi: 10.21608/ejnso.2021.201081
Asmaa Ahmed Bakhiet; Aly Ragaee Abd Hakeem; Ezzat Mohammed Saleh; Mahmoud Farouk Sherif; Ahmed Hamed Mohammed. "Safety and Efficacy of Rifampicin in treatment of Rhinoscleroma, Single Institutional Experience on patients over two years period". EKB Journal Management System, 7, 2, 2021, 23-36. doi: 10.21608/ejnso.2021.201081
Bakhiet, A., Abd Hakeem, A., Saleh, E., Sherif, M., Mohammed, A. (2021). 'Safety and Efficacy of Rifampicin in treatment of Rhinoscleroma, Single Institutional Experience on patients over two years period', EKB Journal Management System, 7(2), pp. 23-36. doi: 10.21608/ejnso.2021.201081
Bakhiet, A., Abd Hakeem, A., Saleh, E., Sherif, M., Mohammed, A. Safety and Efficacy of Rifampicin in treatment of Rhinoscleroma, Single Institutional Experience on patients over two years period. EKB Journal Management System, 2021; 7(2): 23-36. doi: 10.21608/ejnso.2021.201081

Safety and Efficacy of Rifampicin in treatment of Rhinoscleroma, Single Institutional Experience on patients over two years period

Egyptian Journal of Neck Surgery and Otorhinolaryngology
Article 3, Volume 7, Issue 2, September 2021, Page 23-36  XML PDF (859.96 K)
DOI: 10.21608/ejnso.2021.201081
View on SCiNiTO View on SCiNiTO
Authors
Asmaa Ahmed Bakhiet1; Aly Ragaee Abd Hakeem1; Ezzat Mohammed Saleh1; Mahmoud Farouk Sherif2; Ahmed Hamed Mohammedorcid 1
1Otorhinolaryngology, Faculty of Medicine, Assuit University
2Pathology, Faculty of Medicine, Assuit University
Abstract
Introduction: Rhinoscleroma is a chronic granulomatous infectious disease of the upper respiratory tract. It affects the nose in the majority of patients, but the upper air passages, trachea, and bronchi may also be involved either with or without nasal granuloma.
Objectives: To evaluate the efficacy of Rifampicin 300 mg twice daily for six weeks in treating histologically active rhinoscleroma patients. Evaluation of the drawbacks and side effects of Rifampicin used in the treatment of rhinoscleroma.
Patients and Methods: This prospective randomized descriptive clinical trial was conducted from January 2018 to December 2019 on 20 patients diagnosed clinically and histopathologically as rhinoscleroma scheduled for treatment and received the usual regimen given for free by the Ministry of Health in Egypt; Rifampicin 300 mg twice daily one hour before meals for six months.
Results: The impact of medical treatment with Rifampicin on histopathological examination after treatment showing that only 25% of cases are cured.
Conclusion: Rifampicin is a less effective and safe drug in the treatment of active rhinoscleroma. Clinical assessment and histopathological examination are nearly correlated and could be used as a parameter in follow-up and assessment.
Keywords
Rhinoscleroma; Rifampicin; Antibiotics
Statistics
Article View: 405
PDF Download: 238